These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29165087)

  • 1. Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics.
    Holec AD; Mandal S; Prathipati PK; Destache CJ
    Curr HIV Res; 2017; 15(6):411-421. PubMed ID: 29165087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current insights and molecular docking studies of HIV-1 reverse transcriptase inhibitors.
    Singh AK; Kumar A; Arora S; Kumar R; Verma A; Khalilullah H; Jaremko M; Emwas AH; Kumar P
    Chem Biol Drug Des; 2024 Jan; 103(1):e14372. PubMed ID: 37817296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
    Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
    Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).
    De Clercq E
    Adv Pharmacol; 2013; 67():317-58. PubMed ID: 23886005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of anti-HIV-1 drugs.
    Lu XF; Chen ZW
    Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress of bis(heteroaryl)piperazines (BHAPs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) against human immunodeficiency virus type 1 (HIV-1).
    Xu H
    Mini Rev Med Chem; 2010 Jan; 10(1):62-72. PubMed ID: 20380641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
    Piliero PJ
    J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S2-S12. PubMed ID: 15319664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure, Synthesis and Inhibition Mechanism of Nucleoside Analogues as HIV-1 Reverse Transcriptase Inhibitors (NRTIs).
    Yoshida Y; Honma M; Kimura Y; Abe H
    ChemMedChem; 2021 Mar; 16(5):743-766. PubMed ID: 33230979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains.
    Yu F; Li W; Wang L; Dai Y; Lu X; Wang Q; Xie L; Jiang S
    Molecules; 2018 Jul; 23(7):. PubMed ID: 30004408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance.
    Bertoletti N; Chan AH; Schinazi RF; Anderson KS
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33096918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of mitochondrial toxicity of HIV-1 antiretroviral drugs on lipodystrophy and metabolic dysregulation.
    Feeney ER; Mallon PW
    Curr Pharm Des; 2010 Oct; 16(30):3339-51. PubMed ID: 20687890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain.
    de Mulder M; Yebra G; Martín L; Prieto L; Mellado MJ; Rojo P; Muñoz-Fernández MÁ; Jiménez de Ory S; Ramos JT; Holguín A;
    J Antimicrob Chemother; 2011 Oct; 66(10):2362-71. PubMed ID: 21810838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.
    Imaz A; Llibre JM; Mora M; Mateo G; Camacho A; Blanco JR; Curran A; Santos JR; Caballero E; Bravo I; Gayá F; Domingo P; Rivero A; Falcó V; Clotet B; Ribera E
    J Antimicrob Chemother; 2011 Feb; 66(2):358-62. PubMed ID: 21172789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of a single-class maintenance strategy with nucleoside/nucleotide reverse transcriptase inhibitors in HIV/AIDS.
    Sprenger HG; Bierman WF; van der Werf TS; Gisolf EH; Richter C
    Antivir Ther; 2014; 19(7):625-36. PubMed ID: 24429420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations.
    Sörstedt E; Carlander C; Flamholc L; Hejdeman B; Svedhem V; Sönnerborg A; Gisslén M; Yilmaz A
    Int J Antimicrob Agents; 2018 May; 51(5):733-738. PubMed ID: 29371105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emergence of different resistance mechanisms toward nucleoside inhibitors is explained by the properties of the wild type HIV-1 reverse transcriptase.
    Isel C; Ehresmann C; Walter P; Ehresmann B; Marquet R
    J Biol Chem; 2001 Dec; 276(52):48725-32. PubMed ID: 11668180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
    Paton NI; Kityo C; Thompson J; Nankya I; Bagenda L; Hoppe A; Hakim J; Kambugu A; van Oosterhout JJ; Kiconco M; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS;
    Lancet HIV; 2017 Aug; 4(8):e341-e348. PubMed ID: 28495562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.
    Vidal C; García F; Gatell JM; Leal M; Clotet B; Pumarola T; Miró JM; Mallolas J; Ruiz L; Cruceta A; Tortajada C
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):55-60. PubMed ID: 9732070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.